Article
Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor
17 Mar 2022
Abstract excerpt
Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and extraterminal (BET) family, is considered to be a major driver of cancer cell growth and a new target for cancer therapy. Over 30 targeted inhibitors currently in preclinical and clinical trials have significant inhibitory effects on various tumors, including acute myelogenous leukemia (AML), diffuse large B cell lymphoma, prostate cancer,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
